Nanostar Sieving™: A Precise and Scalable Synthesis Method for Oligonucleotides
Oligonucleotides, also known as oligos, are therapeutic strands composed of nucleotides or nucleotide analogues, typically 15-25 nucleotides long, and active at the RNA level. Initially designed for rare diseases, oligos are now rapidly expanding into treatments for more prevalent diseases. However, the growing demand underscores challenges in manufacturing, including scalability, manufacturing cost, and environmental impact.
Nanostar Sieving™ emerges as a disruptive technology in oligo synthesis, overcoming these limitations and facilitating the availability of these promising therapeutics to larger patient populations.
The Advantage of the Nanostar Sieving™ Platform for Oligonucleotide Synthesis
Cost-effective manufacturing
Nanostar Sieving™ has significantly decreased manufacturing costs through an enhanced process characterized by reduced solvent consumption, minimized reagent equivalents, less expensive soluble supports and real-time monitoring of reaction completion.
Unprecedented scalability
Our liquid phase process is highly scalable which will help improve manufacturing efficiency and meet the demand for therapeutics treating prevalent diseases.
Chemistry agnostic platform
This chemistry agnostic platform allows us to use and explore various chemistries and process improvements (e.g P(III), P(V), fragments).
Highly flexible and compatible
The Nanostar Sieving™ platform can be integrated into existing manufacturing assets (solid phase train and small molecule).
Reduced environmental impact
Our process uses a single solvent mixture, allowing the recycling of the used solvent and reducing the total Process Mass Intensity (PMI).